Filing Details
- Accession Number:
- 0001012975-11-000075
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-04-13 20:14:51
- Reporting Period:
- 2011-04-11
- Filing Date:
- 2011-04-13
- Accepted Time:
- 2011-04-13 20:14:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
930553 | Ista Pharmaceuticals Inc | ISTA | Pharmaceutical Preparations (2834) | 330511719 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1196201 | Kathleen Laporte | C/O New Leaf Venture Partners 2500 Sand Hill Road, Suite 203 Menlo Park CA 94025 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-04-11 | 1,615,385 | $1.41 | 8,561,041 | No | 4 | X | Indirect | See footnote |
Common Stock | Disposition | 2011-04-11 | 216,526 | $10.52 | 8,344,515 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | X | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrants (right to buy) | Acquisiton | 2011-04-11 | 1,615,385 | $0.00 | 1,615,385 | $1.41 |
Common Stock | Warrants (right to buy) | Disposition | 2011-04-11 | 1,615,385 | $0.00 | 1,615,385 | $1.41 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,615,385 | No | 4 | P | Indirect | ||
0 | No | 4 | X | Indirect |
Footnotes
- See Footnote 1 in Exhibit 99.1
- See Footnote 2 in Exhibit 99.1
- See Footnote 3 in Exhibit 99.1
- See Footnote 4 in Exhibit 99.1